Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Theodorus B. M. Hakvoort is active.

Publication


Featured researches published by Theodorus B. M. Hakvoort.


Hepatology | 2004

Identification of the leukocyte cell‐derived chemotaxin 2 as a direct target gene of β‐catenin in the liver

Christine Ovejero; Catherine Cavard; Axel Périanin; Theodorus B. M. Hakvoort; Jacqueline L. M. Vermeulen; Cécile Godard; Monique Fabre; Philippe Chafey; Kazuo Suzuki; Béatrice Romagnolo; Satoshi Yamagoe; Christine Perret

To clarify molecular mechanisms underlying liver carcinogenesis induced by aberrant activation of Wnt pathway, we isolated the target genes of β‐catenin from mice exhibiting constitutive activated β‐catenin in the liver. Adenovirus‐mediated expression of oncogenic β‐catenin was used to isolate early targets of β‐catenin in the liver. Suppression subtractive hybridization was used to identify the leukocyte cell‐derived chemotaxin 2 (LECT2) gene as a direct target of β‐catenin. Northern blot and immunohistochemical analyses demonstrated that LECT2 expression is specifically induced in different mouse models that express activated β‐catenin in the liver. LECT2 expression was not activated in livers in which hepatocyte proliferation was induced by a β‐catenin–independent signal. We characterized by mutagenesis the LEF/TCF site, which is crucial for LECT2 activation by β‐catenin. We further characterized the chemotactic property of LECT2 for human neutrophils. Finally, we have shown an up‐regulation of LECT2 in human liver tumors that expressed aberrant activation of β‐catenin signaling; these tumors constituted a subset of hepatocellular carcinomas (HCC) and most of the hepatoblastomas that were studied. In conclusion, our results show that LECT2, which encodes a protein with chemotactic properties for human neutrophils, is a direct target gene of Wnt/β‐catenin signaling in the liver. Since HCC develops mainly in patients with chronic hepatitis or cirrhosis induced by viral or inflammatory factors, understanding the role of LECT2 in liver carcinogenesis is of interest and may lead to new therapeutic perspectives. (HEPATOLOGY 2004;40:167–176.)


Hepatology | 2007

Hepatic HNF4α deficiency induces periportal expression of glutamine synthetase and other pericentral enzymes

Vesna Stanulović; Irene Kyrmizi; Marianna Kruithof-de Julio; Maarten Hoogenkamp; Jacqueline L. M. Vermeulen; Jan M. Ruijter; Iannis Talianidis; Theodorus B. M. Hakvoort; Wouter H. Lamers

In liver, most genes are expressed with a porto‐central gradient. The transcription factor hepatic nuclear‐factor4α (HNF4α) is associated with 12% of the genes in adult liver, but its involvement in zonation of gene expression has not been investigated. A putative HNF4α‐response element in the upstream enhancer of glutamine synthetase (GS), an exclusively pericentral enzyme, was protected against DNase‐I and interacted with a protein that is recognized by HNF4α‐specific antiserum. Chromatin‐immunoprecipitation assays of HNF4α‐deficient (H4LivKO) and control (H4Flox) livers with HNF4α antiserum precipitated the GS upstream enhancer DNA only from H4Flox liver. Identical results were obtained with a histone‐deacetylase1 (HDAC1) antibody, but antibodies against HDAC3, SMRT and SHP did not precipitate the GS upstream enhancer. In H4Flox liver, GS, ornithine aminotransferase (OAT) and thyroid hormone‐receptor β1 (TRβ1) were exclusively expressed in pericentral hepatocytes. In H4LivKO liver, this pericentral expression remained unaffected, but the genes were additionally expressed in the periportal hepatocytes, albeit at a lower level. The expression of the periportal enzyme phosphoenolpyruvate carboxykinase had declined in HNF4α‐deficient hepatocytes. GS‐negative cells, which were present as single, large hepatocytes or as groups of small cells near portal veins, did express HNF4α. Clusters of very small GS‐ and HNF4α‐negative, and PCNA‐ and OV6‐positive cells near portal veins were contiguous with streaks of brightly HNF4α‐positive, OV6‐, PCNA‐, and PEPCK‐dim cells. Conclusion: Our findings show that HNF4α suppresses the expression of pericentral proteins in periportal hepatocytes, possibly via a HDAC1‐mediated mechanism. Furthermore, we show that HNF4α deficiency induces foci of regenerating hepatocytes. (HEPATOLOGY 2007;45:433–444.)


Developmental Dynamics | 2007

Glutamine synthetase is essential in early mouse embryogenesis

Youji He; Theodorus B. M. Hakvoort; Jacqueline L. M. Vermeulen; Wouter H. Lamers; Maria A. Van Roon

Glutamine synthetase (GS) is expressed in a tissue‐specific and developmentally controlled manner, and functions to remove ammonia or glutamate. Furthermore, it is the only enzyme that can synthesize glutamine de novo. Since congenital deficiency of GS has not been reported, we investigated its role in early development. Because GS is expressed in embryonic stem (ES) cells, we generated a null mutant by replacing one GS allele in‐frame with a β‐galactosidase‐neomycine fusion gene. GS+/LacZ mice have no phenotype, but GSLacZ/LacZ mice die at ED3.5, demonstrating GS is essential in early embryogenesis. Although cells from ED2.5 GSLacZ/LacZ embryos and GSGFP/LacZ ES cells survive in vitro in glutamine‐containing medium, these GS‐deficient cells show a reduced fitness in chimera analysis and fail to survive in tetraploid‐complementation assays. The survival of heavily (>90%) chimeric mice up to at least ED16.5 indicates that GS deficiency does not entail cell‐autonomous effects and that, after implantation, GS activity is not essential until at least the fetal period. We hypothesize that GS‐deficient embryos die when they move from the uterine tube to the harsher uterine environment, where the embryo has to catabolize amino acids to generate energy and, hence, has to detoxify ammonia, which requires GS activity. Developmental Dynamics 236:1865–1875, 2007.


The International Journal of Biochemistry & Cell Biology | 2011

The HepaRG cell line is suitable for bioartificial liver application

Ruurdtje Hoekstra; Geert A. A. Nibourg; Tessa V. van der Hoeven; Mariëtte T. Ackermans; Theodorus B. M. Hakvoort; Thomas M. van Gulik; Wouter H. Lamers; Ronald P. J. Oude Elferink; Robert A. F. M. Chamuleau

For bioartificial liver application, cells should meet the following minimal requirements: ammonia elimination, drug metabolism and blood protein synthesis. Here we explore the suitability of HepaRG cells, a human cell line reported to differentiate into hepatocyte clusters and surrounding biliary epithelial-like cells at high density and after exposure to dimethyl sulfoxide (DMSO). The effect of carbamoyl-glutamate (CG), an activator of urea cycle enzyme carbamoylphosphate synthetase (CPS) was studied additionally. The effects of DMSO and/or CG were assessed in presence of (15)NH(4)Cl on HepaRG cells in monolayer. We tested hepatocyte-specific functions at transcript and biochemical level, cell damage parameters and performed immunostainings. Ureagenesis, ammonia/galactose elimination and albumin, glutamine synthetase and CPS transcript levels were higher in -DMSO than +DMSO cultures, probably due to a higher cell content and/or cluster-neighbouring regions contributing to their functionality. DMSO treatment increased cytochrome P450 (CYP) transcript levels and CYP3A4 activity, but also cell damage and repressed hepatic functionality in cluster-neighbouring regions. The levels of ammonia elimination, apolipoprotein A-1 production, and transcription of CYP3A4, CYP2B6 and albumin reached those of primary hepatocytes in either the + or -DMSO cultures. Preconditioning with CG increased conversion of (15)NH(4)Cl into (15)N-urea 4-fold only in -DMSO cultures. Hence, HepaRG cells show high metabolic and synthetic functionality in the absence of DMSO, however, their drug metabolism is only high in the presence of DMSO. An unparalleled broad hepatic functionality, suitable for bioartificial liver application, can be accomplished by combining CG treated -DMSO cultures with +DMSO cultures.


BMC Genomics | 2008

The transcriptomic signature of fasting murine liver

Milka Sokolovic; Aleksandar Sokolović; Diederik Wehkamp; Emiel Ver Loren van Themaat; Dirk R. de Waart; Lisa A. Gilhuijs-Pederson; Yuri Nikolsky; Antoine H. C. van Kampen; Theodorus B. M. Hakvoort; Wouter H. Lamers

BackgroundThe contribution of individual organs to the whole-body adaptive response to fasting has not been established. Hence, gene-expression profiling, pathway, network and gene-set enrichment analysis and immunohistochemistry were carried out on mouse liver after 0, 12, 24 and 72 hours of fasting.ResultsLiver wet weight had declined ~44, ~5, ~11 and ~10% per day after 12, 24, 48 and 72 hours of fasting, respectively. Liver structure and metabolic zonation were preserved. Supervised hierarchical clustering showed separation between the fed, 12–24 h-fasted and 72 h-fasted conditions. Expression profiling and pathway analysis revealed that genes involved in amino-acid, lipid, carbohydrate and energy metabolism responded most significantly to fasting, that the response peaked at 24 hours, and had largely abated by 72 hours. The strong induction of the urea cycle, in combination with increased expression of enzymes of the tricarboxylic-acid cycle and oxidative phosphorylation, indicated a strong stimulation of amino-acid oxidation peaking at 24 hours. At this time point, fatty-acid oxidation and ketone-body formation were also induced. The induction of genes involved in the unfolded-protein response underscored the cell stress due to enhanced energy metabolism. The continuous high expression of enzymes of the urea cycle, malate-aspartate shuttle, and the gluconeogenic enzyme Pepck and the re-appearance of glycogen in the pericentral hepatocytes indicate that amino-acid oxidation yields to glucose and glycogen synthesis during prolonged fasting.ConclusionThe changes in liver gene expression during fasting indicate that, in the mouse, energy production predominates during early fasting and that glucose production and glycogen synthesis become predominant during prolonged fasting.


Journal of Biological Chemistry | 2010

Glutamine synthetase in muscle is required for glutamine production during fasting and extrahepatic ammonia detoxification.

Youji He; Theodorus B. M. Hakvoort; S. Eleonore Köhler; Jacqueline L. M. Vermeulen; D. Rudi de Waart; Chiel C. de Theije; Gabrie A.M. Ten Have; Hans M.H. van Eijk; Cindy Kunne; W. T. Labruyere; Sander M. Houten; Milka Sokolovic; Jan M. Ruijter; Nicolaas E. P. Deutz; Wouter H. Lamers

The main endogenous source of glutamine is de novo synthesis in striated muscle via the enzyme glutamine synthetase (GS). The mice in which GS is selectively but completely eliminated from striated muscle with the Cre-loxP strategy (GS-KO/M mice) are, nevertheless, healthy and fertile. Compared with controls, the circulating concentration and net production of glutamine across the hindquarter were not different in fed GS-KO/M mice. Only a ∼3-fold higher escape of ammonia revealed the absence of GS in muscle. However, after 20 h of fasting, GS-KO/M mice were not able to mount the ∼4-fold increase in glutamine production across the hindquarter that was observed in control mice. Instead, muscle ammonia production was ∼5-fold higher than in control mice. The fasting-induced metabolic changes were transient and had returned to fed levels at 36 h of fasting. Glucose consumption and lactate and ketone-body production were similar in GS-KO/M and control mice. Challenging GS-KO/M and control mice with intravenous ammonia in stepwise increments revealed that normal muscle can detoxify ∼2.5 μmol ammonia/g muscle·h in a muscle GS-dependent manner, with simultaneous accumulation of urea, whereas GS-KO/M mice responded with accumulation of glutamine and other amino acids but not urea. These findings demonstrate that GS in muscle is dispensable in fed mice but plays a key role in mounting the adaptive response to fasting by transiently facilitating the production of glutamine. Furthermore, muscle GS contributes to ammonia detoxification and urea synthesis. These functions are apparently not vital as long as other organs function normally.


Glia | 2010

Glutamine Synthetase Deficiency in Murine Astrocytes Results in Neonatal Death

Youji He; Theodorus B. M. Hakvoort; Jacqueline L. M. Vermeulen; W. T. Labruyere; D. Rudi de Waart; W. Saskia van der Hel; Jan M. Ruijter; H.B.M. Uylings; Wouter H. Lamers

Glutamine synthetase (GS) is a key enzyme in the “glutamine‐glutamate cycle” between astrocytes and neurons, but its function in vivo was thus far tested only pharmacologically. Crossing GSfl/lacZ or GSfl/fl mice with hGFAP‐Cre mice resulted in prenatal excision of the GSfl allele in astrocytes. “GS‐KO/A” mice were born without malformations, did not suffer from seizures, had a suckling reflex, and did drink immediately after birth, but then gradually failed to feed and died on postnatal day 3. Artificial feeding relieved hypoglycemia and prolonged life, identifying starvation as the immediate cause of death. Neuronal morphology and brain energy levels did not differ from controls. Within control brains, amino acid concentrations varied in a coordinate way by postnatal day 2, implying an integrated metabolic network had developed. GS deficiency caused a 14‐fold decline in cortical glutamine and a sevenfold decline in cortical alanine concentration, but the rising glutamate levels were unaffected and glycine was twofold increased. Only these amino acids were uncoupled from the metabolic network. Cortical ammonia levels increased only 1.6‐fold, probably reflecting reduced glutaminolysis in neurons and detoxification of ammonia to glycine. These findings identify the dramatic decrease in (cortical) glutamine concentration as the primary cause of brain dysfunction in GS‐KO/A mice. The temporal dissociation between GSfl elimination and death, and the reciprocal changes in the cortical concentration of glutamine and alanine in GS‐deficient and control neonates indicate that the phenotype of GS deficiency in the brain emerges coincidentally with the neonatal activation of the glutamine‐glutamate and the associated alanine‐lactate cycles.


Cancer Gene Therapy | 2005

Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy

Daniëlle A.M. Heideman; Renée M. Overmeer; Victor W. van Beusechem; Wouter H. Lamers; Theodorus B. M. Hakvoort; Peter J.F. Snijders; Mikael E. Craanen; G. Johan A. Offerhaus; Chris J. L. M. Meijer; Winald R. Gerritsen

NK4 is an hepatocyte growth factor (HGF)-antagonist and a broad angiogenesis inhibitor. NK4 gene therapy has confirmed antitumor efficacy on cancers with intact HGF-cMET signaling pathway. However, the feasibility to treat tumors in which the effect of the HGF-cMET signaling pathway is less unambiguous or may even be inhibitory on carcinogenesis, such as hepatocellular carcinoma (HCC) with NK4 needs further assessment. Therefore, we evaluated the effects of adenoviral vector-mediated expression of NK4 on the biological behavior of a series of HCC cell lines in vitro and on HepG2 xenografts in vivo. In vitro, transduction of HCC cell lines with the replication-deficient recombinant adenoviral vector AdCMV.NK4 resulted in significant inhibition of proliferation over and above the antimitogenic effects of HGF. In addition, HGF-induced scattering and invasion through matrigel were inhibited effectively. Moreover, transduced HCC cells produced sufficient amounts of NK4 protein to achieve bystander effects involving reduced migration of nontransduced tumor cells and reduced proliferation of endothelial cells. Finally, treatment of established HepG2 xenografts with AdCMV.NK4 resulted in significant tumor growth delay and significant reduction of intratumoral microvessel density. In conclusion, NK4 gene therapy is a promising strategy to treat HCC based on the pleiotropic functions of NK4 interfering with tumor growth, invasion, metastasis and angiogenesis.


Biochimica et Biophysica Acta | 2013

Prevention and reversal of hepatic steatosis with a high-protein diet in mice

Sonia C. Garcia-Caraballo; Tine M. Comhair; Fons Verheyen; Ingrid C. Gaemers; Frank G. Schaap; Sander M. Houten; Theodorus B. M. Hakvoort; Cornelis H.C. Dejong; Wouter H. Lamers; S. Eleonore Koehler

UNLABELLED The hallmark of NAFLD is steatosis of unknown etiology. We tested the effect of a high-protein (HP)(2) diet on diet-induced steatosis in male C57BL/6 mice with and without pre-existing fatty liver. Mice were fed all combinations of semisynthetic low-fat (LF) or high-fat (HF) and low-protein (LP) or HP diets for 3weeks. To control for reduced energy intake by HF/HP-fed mice, a pair-fed HF/LP group was included. Reversibility of pre-existing steatosis was investigated by sequentially feeding HF/LP and HF/HP diets. HP-containing diets decreased hepatic lipids to ~40% of corresponding LP-containing diets, were more efficient in this respect than reducing energy intake to 80%, and reversed pre-existing diet-induced steatosis. Compared to LP-containing diets, mice fed HP-containing diets showed increased mitochondrial oxidative capacity (elevated Pgc1α, mAco, and Cpt1 mRNAs, complex-V protein, and decreased plasma free and short-chain acyl-carnitines, and [C0]/[C16+C18] carnitine ratio); increased gluconeogenesis and pyruvate cycling (increased PCK1 protein and fed plasma-glucose concentration without increased G6pase mRNA); reduced fatty-acid desaturation (decreased Scd1 expression and [C16:1n-7]/[C16:0] ratio) and increased long-chain PUFA elongation; a selective increase in plasma branched-chain amino acids; a decrease in cell stress (reduced phosphorylated eIF2α, and Fgf21 and Chop expression); and a trend toward less inflammation (lower Mcp1 and Cd11b expression and less phosphorylated NFκB). CONCLUSION HP diets prevent and reverse steatosis independently of fat and carbohydrate intake more efficiently than a 20% reduction in energy intake. The effect appears to result from fuel-generated, highly distributed small, synergistic increases in lipid and BCAA catabolism, and a decrease in cell stress.


Journal of Biological Chemistry | 2011

Interorgan Coordination of the Murine Adaptive Response to Fasting

Theodorus B. M. Hakvoort; Perry D. Moerland; Raoul J. J. M. Frijters; Aleksandar Sokolović; W. T. Labruyere; Jacqueline L. M. Vermeulen; Emiel Ver Loren van Themaat; Timo M. Breit; Floyd Wittink; Antoine H. C. van Kampen; Arthur J. Verhoeven; Wouter H. Lamers; Milka Sokolovic

Starvation elicits a complex adaptive response in an organism. No information on transcriptional regulation of metabolic adaptations is available. We, therefore, studied the gene expression profiles of brain, small intestine, kidney, liver, and skeletal muscle in mice that were subjected to 0–72 h of fasting. Functional-category enrichment, text mining, and network analyses were employed to scrutinize the overall adaptation, aiming to identify responsive pathways, processes, and networks, and their regulation. The observed transcriptomics response did not follow the accepted “carbohydrate-lipid-protein” succession of expenditure of energy substrates. Instead, these processes were activated simultaneously in different organs during the entire period. The most prominent changes occurred in lipid and steroid metabolism, especially in the liver and kidney. They were accompanied by suppression of the immune response and cell turnover, particularly in the small intestine, and by increased proteolysis in the muscle. The brain was extremely well protected from the sequels of starvation. 60% of the identified overconnected transcription factors were organ-specific, 6% were common for 4 organs, with nuclear receptors as protagonists, accounting for almost 40% of all transcriptional regulators during fasting. The common transcription factors were PPARα, HNF4α, GCRα, AR (androgen receptor), SREBP1 and -2, FOXOs, EGR1, c-JUN, c-MYC, SP1, YY1, and ETS1. Our data strongly suggest that the control of metabolism in four metabolically active organs is exerted by transcription factors that are activated by nutrient signals and serves, at least partly, to prevent irreversible brain damage.

Collaboration


Dive into the Theodorus B. M. Hakvoort's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Youji He

University of Amsterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge